NASDAQ:TBPH Theravance Biopharma (TBPH) Stock Price, News & Analysis $11.24 -0.06 (-0.49%) As of 09:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Theravance Biopharma Stock (NASDAQ:TBPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theravance Biopharma alerts:Sign Up Key Stats Today's Range$11.17▼$11.2650-Day Range$9.14▼$11.6552-Week Range$7.44▼$11.88Volume3,508 shsAverage Volume254,174 shsMarket Capitalization$562.25 millionP/E RatioN/ADividend YieldN/APrice Target$16.60Consensus RatingModerate Buy Company Overview Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. Read More Theravance Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreTBPH MarketRank™: Theravance Biopharma scored higher than 32% of companies evaluated by MarketBeat, and ranked 753rd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingTheravance Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageTheravance Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Theravance Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Theravance Biopharma are expected to grow in the coming year, from ($1.09) to $0.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is -9.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is -9.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Theravance Biopharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.06% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently increased by 4.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.06% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently increased by 4.52%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News Sentiment0.03 News SentimentTheravance Biopharma has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Theravance Biopharma this week, compared to 2 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $491,800.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Theravance Biopharma is held by insiders.Percentage Held by Institutions99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Theravance Biopharma's insider trading history. Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Stock News HeadlinesTheravance Biopharma to Participate in an Upcoming Investor ConferenceJuly 23 at 6:00 AM | prnewswire.comBrokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60July 17, 2025 | americanbankingnews.comBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.July 24 at 2:00 AM | Golden Portfolio (Ad)Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street ZenJuly 14, 2025 | americanbankingnews.comTBPH Theravance Biopharma, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comTheravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPAJune 26, 2025 | prnewswire.comTheravance Shares Rise Premarket on Sale of Trelegy RoyaltiesJune 2, 2025 | marketwatch.comTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...June 2, 2025 | gurufocus.comSee More Headlines TBPH Stock Analysis - Frequently Asked Questions How have TBPH shares performed this year? Theravance Biopharma's stock was trading at $9.41 on January 1st, 2025. Since then, TBPH shares have increased by 19.5% and is now trading at $11.2450. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) posted its quarterly earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.16. The biopharmaceutical company earned $15.39 million during the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative trailing twelve-month return on equity of 32.37%. Read the conference call transcript. Who are Theravance Biopharma's major shareholders? Top institutional investors of Theravance Biopharma include Assenagon Asset Management S.A. (0.05%) and Ballentine Partners LLC (0.03%). Insiders that own company stock include Richard A Graham and Rhonda Farnum. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/08/2025Today7/24/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Theravance Biopharma$16.60 High Price Target$25.00 Low Price Target$9.00 Potential Upside/Downside+46.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.42 million Net Margins-89.38% Pretax Margin-74.08% Return on Equity-32.37% Return on Assets-16.48% Debt Debt-to-Equity RatioN/A Current Ratio4.77 Quick Ratio4.77 Sales & Book Value Annual Sales$64.38 million Price / Sales8.78 Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book3.17Miscellaneous Outstanding Shares50,000,000Free Float46,551,000Market Cap$565 million OptionableOptionable Beta-0.02 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:TBPH) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.